Children’s National is the largest provider of Sickle Cell Disease (SCD) care for the greater DC area and the 2nd largest (after Atlanta) pediatric SCD center in the country. CHB’s investments support the provision of critical information on SCD treatments. One in 500 African American children are born with SCD and the only cure is the stem cell transplant. As medical advances surrounding improved treatments for patients living with sickle cell disease, survival rates have increased significantly. Over 98% of children born today with sickle cell disease will survive to adulthood. Dr. Emily Meier cares for more than 1,200 sickle cell patients at Children’s National Medical Center. To ensure that her patients continue to thrive when they leave her care, she has hosted a series of symposia that provide information on treatment options, including bone marrow transplantation as a curative therapy; updates on SCD research and access to SCD experts and patients and families who have been successfully treated; and access to transition care from Children’s National to adult-centered care to ensure that the patients continue to thrive into adulthood. Since 2011, CHB has invested nearly $18,000 in support of symposia on Sickle Cell Disease treatment options, and for critical research into the medical and psychosocial factors that influence families’ decisions about whether or not to pursue the treatment options available.
Since 2011, CHB has invested nearly $18,000 in support of these symposia and for critical research into the medical and psychosocial factors that influence families’ decisions about whether or not to pursue the treatment options available.